Trial Profile
A study investigating the effect of crizotinib and comparing different ALK tests in patients with non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Aug 2015 New trial record